Pancreatic Cancer Research

ResearcherUniversity Of Texas Med Br GalvestonActive in the last 2 years

Taylor Sohn Riall

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5917-8784; OpenAlex author ID A5027685888, A5159815964; NIH RePORTER profile ID 8875932. Sources: OpenAlex.

Their work

Papers
21 (first author 1, last author 12)
Trials
0
Grants
1
Labs led
3
Collaborators
30
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers, 1 grant · 2013: 3 papers · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: none · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: 2 papers · 2026: 2 papers

Papers 21

  1. Chemotherapy dose intensity and outcomes in resected pancreatic cancer. Last author DOI 10.1016/j.gassur.2025.102287↗
  2. Association of Neoadjuvant Therapy on Pathologic and Clinical Outcomes for Pancreatic Adenocarcinoma. Last author DOI 10.1016/j.jss.2025.11.065↗
  3. Spatial Biology and Organoid Technologies Reveal a Potential Therapy-Resistant Cancer Stem Cell Population in Pancreatic Ductal Adenocarcinoma Co-author DOI 10.1101/2025.05.22.655586↗
  4. Perioperative Nutrition Screen (PONS) Predicts Outcomes in Patients Undergoing Surgery for Pancreatic Cancer: A Retrospective Analysis Co-author DOI 10.21203/rs.3.rs-7195049/v1↗
  5. Impact of facility type on survival after pancreatoduodenectomy for small pancreatic adenocarcinoma (≤ 2 cm). Co-author DOI 10.1016/j.amjsurg.2020.10.022↗
  6. Survival after Margin-Positive Resection in the Era of Modern Chemotherapy for Pancreatic Cancer: Do Patients Still Benefit? Last author DOI 10.1016/j.jamcollsurg.2021.02.020↗
  7. Pancreatic Cancer Lymph Node Resection Revisited: A Novel Calculation of Number of Lymph Nodes Required. Last author DOI 10.1016/j.jamcollsurg.2018.12.031↗
  8. Pancreatic Cancer Lymph Node Status: An Unsolved Problem that Impacts Recommendation Despite Guidelines: In reply to Hyer and colleagues. First author DOI 10.1016/j.jamcollsurg.2019.03.003↗
  9. Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer. Co-author DOI 10.1038/s41388-018-0650-0↗
  10. Reduced morbidity with minimally invasive distal pancreatectomy for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2017.01.014↗
  11. Trends in Receipt and Timing of Multimodality Therapy in Early-Stage Pancreatic Cancer. Last author DOI 10.1007/s11605-015-2952-7↗
  12. Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates? Co-author DOI 10.1007/s11605-014-2620-3↗
  13. Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma. Last author DOI 10.1016/j.surg.2014.03.001↗
  14. Evaluating comparative effectiveness with observational data: endoscopic ultrasound and survival in pancreatic cancer. Last author DOI 10.1002/cncr.28295↗
  15. Individualizing care for locoregional pancreatic cancer? Co-author DOI 10.1016/j.jss.2011.10.041↗
  16. Current trends in preoperative biliary stenting in patients with pancreatic cancer. Last author DOI 10.1016/j.surg.2013.03.016↗
  17. The effect of depression on stage at diagnosis, treatment, and survival in pancreatic adenocarcinoma. Last author DOI 10.1016/j.surg.2012.06.010↗
  18. Surveillance of pancreatic cancer patients after surgical resection. Last author DOI 10.1245/s10434-011-2152-y↗
  19. Hospital and medical care days in pancreatic cancer. Last author DOI 10.1245/s10434-012-2326-2↗
  20. End-of-life care in Medicare beneficiaries dying with pancreatic cancer. Last author DOI 10.1002/cncr.26115↗
  21. Resection benefits older adults with locoregional pancreatic cancer despite greater short-term morbidity and mortality. Co-author DOI 10.1111/j.1532-5415.2011.03353.x↗

Grants 1

  1. Underutilization of Surgical Resection in Patients with Pancreatic Cancer K07CA130983↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mohammad R. Khreiss · 4 shared papers, 2021–2026 · strength 1.07
  2. Nicholas Galouzis · 2 shared papers, 2026 · strength 0.65
  3. Amanda Kathleen Arrington · 3 shared papers, 2019–2021 · strength 0.50
  4. Kristin M. Sheffield · 8 shared papers, 2011–2014 · strength 0.31
  5. Faisal Jehan · 1 shared paper, 2025 · strength 0.27
  6. Abhishek D. Parmar · 5 shared papers, 2013–2016 · strength 0.26
  7. Rachna T. Shroff · 1 shared paper, 2025 · strength 0.17
  8. Jayati L. Chakrabarti · 1 shared paper, 2025 · strength 0.17
  9. Pritha Adhikary · 1 shared paper, 2025 · strength 0.17
  10. Payton D. Stevens · 1 shared paper, 2025 · strength 0.17
  11. Yana L. Zavros · 1 shared paper, 2025 · strength 0.17
  12. Gregory Lawrence Beatty · 1 shared paper, 2025 · strength 0.17
  13. Yong‐Fang Kuo · 5 shared papers, 2011–2013 · strength 0.17
  14. James S. Goodwin · 4 shared papers, 2011–2013 · strength 0.14
  15. Felipe B. Maegawa · 1 shared paper, 2021 · strength 0.14
  16. Ioannis T. Konstantinidis · 1 shared paper, 2021 · strength 0.14
  17. Henry Anthony Pitt · 2 shared papers, 2015–2017 · strength 0.14
  18. Kimberly M. Brown · 2 shared papers, 2013 · strength 0.12
  19. Casey A. Boyd · 3 shared papers, 2011–2012 · strength 0.10
  20. Sejin Chung · 1 shared paper, 2019 · strength 0.09
  21. Vishnu Muthuraj Kumarasamy · 1 shared paper, 2019 · strength 0.09
  22. Erik S. Knudsen · 1 shared paper, 2019 · strength 0.09
  23. Agnieszka Katarzyna Witkiewicz · 1 shared paper, 2019 · strength 0.09
  24. Anastasia Plotkin · 1 shared paper, 2017 · strength 0.08
  25. Eugene P. Ceppa · 1 shared paper, 2017 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.